Insider Purchases: Inside the Buy
Tag: Short Squeeze
🛒 Albertsons (ACI): Wall Street Gave Up. One Executive Just Invested $1.96 Million.
Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.
🏰 RH (NYSE: RH): Insider Buying, 34% Short Interest, and a Luxury Turnaround Worth Watching
RH isn't just selling luxury furniture anymore—it's trying to redefine luxury living. With a major insider purchase, elevated short interest, ambitious global expansion, and Wall Street split on the outlook, RH may be one of today's most intriguing turnaround stories.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🧠 Cognizant (CTSH): The Impossible Float Monopoly, Project Leap, and a 9x Multiple GARP Arbitrage
Cognizant may be one of the market's most overlooked AI transformation stories. Strong bookings, aggressive buybacks, and a surprisingly cheap valuation suggest investors may be pricing the company too pessimistically.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.
🚀 Upstart Stock: Founder Buys $5M as AI Lending Underdog Faces Short-Squeeze Setup
Upstart stock is back in Wall Street’s drama zone: insider buying, massive short interest, AI lending growth, cash-flow concerns, and a possible bank-charter catalyst. High risk? Absolutely. Boring? Not even close.
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
MTN Stock Analysis 2026: Why Rob Katz’s $5M Buy Signals a Peak Opportunity in Vail Resorts
Vail Resorts (MTN) just endured one of the worst snowfall seasons in decades—yet insiders are buying millions in stock. With a powerful Epic Pass model, heavy institutional ownership, and rising short interest, this mountain stock may be setting up for a contrarian move.